CGON

CG Oncology is a late-stage clinical biopharma whose entire value rests on one asset: cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The science is genuinely promising — the 10-K reports 'potentially best-in-disease' Phase 3 data in BCG-unresponsive NMIBC, FDA Fast Track and Breakthrough Therapy designations, and a BLA initiated in Q4 2025 and expected to complete in 2026, addressing a market the company estimates at up to 150,000 patients across indications. A bladder-sparing alternative to radical cystectomy is a meaningful unmet need.

But as an equity, this is not investable on fundamentals — the rubric's 'avoid' case (unprofitable, single-asset, unknowable binary risk) applies. The company is effectively pre-revenue ($4.04M, a rounding error), lost $161M in FY2025, and burned $132M of operating cash. The headline ratios are meaningless: a P/S of 1,276.6, a negative P/E (-29.4), and an operating margin of -4,722%. Cash on the balance-sheet line dropped 87.4% to $32.5M, though total current assets of $759M indicate the bulk of the $753M equity sits in marketable securities funding the trials. The 10.8% share-count increase reflects ongoing dilution to fund the burn.